Flibanserin
If you are experiencing low sexual desire, some alternative methods may work better without Addyi’s harmful side effects.
FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org
or (202) 682-6240
FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org
Flibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women.
“My doctor prescribed me Addyi for HSDD. I cannot afford it and my insurance does not cover it. Are there any other resources to get this medication?”
Taken from the March/April 2018 issue of The Women’s Health Activist Newsletter. In 2015, Valeant, a pharmaceutical giant known for price gouging and shady business practices paid $1 billion in cash for a flawed sexual enhancement drug marketed to women…
Popular culture tells us that many women lose interest in sex during or after menopausal transition, but those ageist and sexist messages aren’t supported by good scientific research. We want you to have the facts and offer a few helpful remedies.
FOR IMMEDIATE RELEASE
Contact: Shaniqua Seth at sseth@nwhn.org or 202.682-2640, ext. 225
Click image to download PDF of the report card. Report Card References 1 – Addyi’s FDA Warning Addyi’s life-threatening side effects were so grave that they warranted the strictest possible warning by the FDA—a “black box warning.” Those side effects…